Every Form 4 that Myriad Genetics Inc (MYGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
MYRIAD GENETICS INC (MYGN) reported that its Chief Financial Officer, Benjamin Richard Wheeler, had 2,555 shares of common stock withheld on September 21, 2026 to satisfy tax withholding obligations linked to vesting restricted stock units. The shares were valued at $4.01 per share for this purpose. After this withholding, Wheeler directly holds 287,193 shares of MYGN common stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC (MYGN) disclosed an "Exit" Form 4 for Brian J. Donnelly, who, effective September 16, 2026, no longer serves as Chief Commercial Officer and is therefore no longer subject to Section 16 reporting. The filing reports Donnelly’s continuing direct holdings of common stock and performance-based restricted stock units, but no new transactions or trades. No Rule 10b5-1 plan is reported.
MYRIAD GENETICS INC (symbol: MYGN) is the issuer of record for a Form 4 filing submitted to the SEC. Sikri Vishal reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC (MYGN) reported that EVP, Commercial Vishal Sikri received a grant of 257,731 time-based restricted stock units of common stock on September 16, 2026. The award was made under the company’s 2026 Equity Incentive Plan and vests in three equal annual installments.
Each restricted stock unit represents a contingent right to receive one share of common stock. Following this grant, Sikri holds 351,224 shares of MYGN common stock directly. No Rule 10b5-1 trading plan is reported for this award.
MYRIAD GENETICS INC (MYGN) reported a Form 4 for Chief Legal Officer Jennifer Lynne Fox showing that on September 3, 2026, 4,398 shares of Common Stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These withheld shares were treated as a disposition for reporting purposes at $3.23 per share, based on the closing price on that date, and were not an open-market sale. After this tax-withholding event, Fox directly held 305,964 shares of MYGN Common Stock. No Rule 10b5-1 trading plan is reported for this transaction.
MYRIAD GENETICS INC executive Benjamin Richard Wheeler, Chief Financial Officer, reported a Form 4 transaction involving company common stock. On August 16, 2026, 8,761 shares were withheld by the issuer to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. After this tax-withholding disposition, Wheeler’s directly held common stock position is 289,748 shares.
Myriad Genetics director Daniel Skovronsky filed a Form 4 reporting his direct holdings in the company. The filing lists ownership of 195,507 shares of Common Stock after the reported entry. The record is characterized as a holdings entry, not as a new purchase or sale.
MYRIAD GENETICS INC President and CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026. The shares were obtained at $3.936 per share under the company’s Amended and Restated 2012 Employee Stock Purchase Plan, as a compensation-related award.
After this acquisition, Raha directly holds 1,068,083 shares of Myriad Genetics common stock. This filing reflects a routine, plan-based share purchase rather than an open-market buy or sell decision.
Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company’s Amended and Restated 2012 Employee Stock Purchase Plan. The shares were acquired at a price of $3.936 per share in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c).
After this acquisition, Donnelly directly holds 573,363 shares of Myriad Genetics common stock, indicating this is a relatively small, routine, compensation-related increase in his overall equity position rather than an open-market purchase.
Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of Common Stock in an open-market transaction. The shares were sold on 2026-06-08 at a weighted average price of $4.4562 per share, in multiple trades ranging from $4.37 to $4.63.
After this sale, Kumar directly owns 171,889 shares of Myriad Genetics Common Stock. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
Myriad Genetics director Daniel Skovronsky received an equity award of 59,701 shares of common stock in the form of restricted stock units. The grant was made at no cash cost to him and represents compensation rather than an open-market purchase.
Each restricted stock unit converts into one share of Myriad Genetics common stock and will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this award, Skovronsky holds a total of 195,507 shares of common stock directly.
Newcomer Lee Nisley reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Lee Nisley Newcomer received a grant of restricted stock units. The Form 4 shows an award of 59,701 shares of common stock-equivalent units at no purchase price under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan.
Each restricted stock unit represents one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. After this award, Newcomer directly holds 191,842 shares or share-equivalent units in total.
Davis Mark Steven reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics director Mark Steven Davis received a grant of 59,701 restricted stock units (RSUs) of common stock. The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan and carries no purchase price.
Each RSU represents a right to receive one Myriad Genetics common share and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Davis directly holds 106,665 shares of common stock, reflecting his updated ownership position.
Phanstiel S. Louise reported acquisition or exercise transactions in this Form 4 filing.
Myriad Genetics Inc. director S. Louise Phanstiel received an equity award of 59,701 restricted stock units (RSUs). The award was granted under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan at no cash cost to the director.
Each RSU represents a contingent right to receive one share of Myriad Genetics common stock and will vest upon the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant. After this grant, Phanstiel directly holds 341,652 shares of common stock, reflecting her updated ownership position including the new award.
Dreismann Heinrich reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Heinrich Dreismann received a grant of 59,701 restricted stock units of common stock. The award was made at no cash cost per share and is part of the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a right to receive one common share and will vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting. Following this equity award, Dreismann directly holds 231,145 shares of Myriad Genetics common stock.
Reitan Colleen F reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Colleen F. Reitan received an equity grant of 59,701 shares of common stock in the form of restricted stock units under the company’s 2026 Employee, Director and Consultant Equity Incentive Plan. Following this award, she directly holds 152,030 shares of common stock.
Each restricted stock unit represents a right to receive one share of common stock and will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant. This is a compensation-related award rather than an open-market share purchase.
Bisaro Paul reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Paul Bisaro received an equity award in the form of 59,701 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents a right to one share and will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting. After this grant, Bisaro directly holds 157,142 shares of common stock.
Kumar Rashmi reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC director Rashmi Kumar received an equity grant of 59,701 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash cost and bring Kumar’s direct holdings to 186,889 shares. Each RSU represents a contingent right to receive one share of common stock and will vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting.
Jampa Raj reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Technology Officer Raj Jampa received an equity grant of 251,889 restricted stock units. The award has no cash purchase price and represents a contingent right to receive an equal number of common shares. According to the terms, the units vest in four equal annual installments beginning on the first anniversary of the grant date, aligning the CTO’s compensation with long-term company performance.
Myriad Genetics director Paul Bisaro reported an open-market purchase of 7,500 shares of Common Stock at $3.685 per share. After this transaction, he directly holds 97,441 shares. This filing highlights a personal increase in his equity stake in the company.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly had 55,975 shares of Common Stock withheld at $4.80 per share to cover tax obligations. These shares were withheld in connection with the vesting of previously granted restricted stock units, and he now directly holds 568,363 shares.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-withholding disposition of company stock. On April 14, 2026, 1,069 shares of Myriad Genetics common stock were withheld by the company at $4.91 per share to cover his tax obligations from previously granted restricted stock units vesting. After this withholding, Verratti directly holds 629,646 shares of Myriad Genetics common stock, indicating that the transaction represents a very small portion of his overall equity position and does not reflect an open-market sale.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-withholding transaction tied to equity compensation. On April 14, 2026, 946 shares of Common Stock were withheld by the company at $4.91 per share to cover tax obligations from previously granted restricted stock units vesting. After this withholding, Muzzey directly holds 326,310 shares of Myriad Genetics common stock.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding. On March 22, 2026, 2,019 shares of Myriad Genetics common stock were withheld by the company at $4.58 per share to cover tax obligations from vesting restricted stock units.
These shares were not sold in the open market but delivered back to the issuer to satisfy taxes. After this tax-withholding disposition, Muzzey directly holds 327,256 shares of Myriad Genetics common stock, indicating the transaction affects only a small portion of his overall equity position.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding. On March 22, 2026, 2,055 shares of Common Stock were disposed of at $4.58 per share to satisfy tax obligations tied to vesting restricted stock units. The number of shares withheld was based on the March 20, 2026 closing price. After this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.
MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting. The withheld shares were valued at $4.58 per share, based on the closing price on March 20, 2026.
These shares were not sold in the open market but retained by the issuer to satisfy tax withholding requirements. After this tax-withholding disposition, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.
MYRIAD GENETICS INC Chief Technology Officer Kevin Richard Haas reported share dispositions that were entirely for tax withholding. Over March 13–15, 2026, a total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units.
These F-code transactions are not open-market sales and do not reflect discretionary selling activity. After these tax-withholding events, Haas continues to hold 180,022 shares of Common Stock directly.
MYRIAD GENETICS INC Chief People Officer Shereen Solaiman received a large equity award and had shares withheld for taxes. On March 12, 2026, she was granted 173196 time-based restricted stock units under the 2017 equity incentive plan, vesting in three equal annual installments starting on the first anniversary of the grant.
On March 13 and 14, 2026, the company withheld 8899 and 5784 shares of common stock, respectively, to cover tax obligations tied to vesting of previously granted restricted stock units, based on a share price of $4.6600. After these tax-withholding dispositions, she directly holds 267801 shares of common stock.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported equity compensation activity and related tax withholding transactions in company stock. On March 12, 2026, he received 173,196 time-based restricted stock units under the 2017 equity incentive plan, each representing one share of common stock vesting in three equal annual installments beginning on the first anniversary of the grant.
On March 13–15, 2026, a total of 37,799 shares of common stock were withheld by the company at $4.66 per share to satisfy tax obligations on the vesting of previously granted time-based and performance-based restricted stock units. These F-code transactions are share-withholding for taxes rather than open-market sales. After these transactions, Muzzey directly holds 329,275 shares of common stock.
MYRIAD GENETICS INC Chief Legal Officer Jennifer Lynne Fox reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, she acquired 195,876 time-based restricted stock units granted under the 2017 Employee, Director and Consultant Equity Incentive Plan, with each unit representing one share of common stock that vests in three equal annual installments beginning on the first anniversary of the grant date. On March 13, 2026, 5,995 shares were withheld by the company at a price of $4.66 per share to satisfy tax obligations related to previously vesting restricted stock units. Following these transactions, she directly holds 310,362 shares of common stock.
Donnelly Brian J reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly reported an equity compensation grant of 226,804 shares of common stock in the form of time-based restricted stock units at a price of $0.00 per share.
Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date. Following this award, Donnelly holds 624,338 shares of common stock directly.
Myriad Genetics’ Chief Operating Officer Mark Verratti reported routine equity compensation activity. On March 12, 2026, he acquired 247,423 time-based restricted stock units, each representing one future share that vests in three equal annual installments starting one year after the grant.
On March 13–15, 2026, a total of 29,289 shares of common stock were withheld at $4.66 per share to cover tax obligations tied to the vesting of previously granted time-based and performance-based restricted stock units. After these transactions, Verratti directly held 632,770 shares of Myriad Genetics common stock.
Myriad Genetics Chief Financial Officer Benjamin Richard Wheeler reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, he received 206,186 time-based restricted stock units, each representing one future share, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Between March 13 and March 15, 2026, a total of 4,752 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted time-based and performance-based restricted stock units. These are tax-withholding dispositions rather than open-market sales. After these transactions, Wheeler directly holds 299,058 shares of Myriad Genetics common stock.
Myriad Genetics President and CEO Samraat S. Raha reported equity compensation and related tax withholding transactions in common stock. On March 12, 2026, he received a grant of 618,557 time-based restricted stock units, each representing one future share, vesting in three equal annual installments starting on the first anniversary of the grant date.
On March 13 and 14, 2026, a total of 47,120 shares of common stock were withheld by the company at $4.66 per share to cover tax obligations from previously vesting restricted stock units. After these transactions, Raha directly owns 1,064,541 shares of Myriad Genetics common stock.
Myriad Genetics President and CEO Samraat S. Raha reported an open-market purchase of 40,000 shares of common stock. The shares were bought at a weighted average price of $4.9961 per share in multiple trades between $4.97 and $5.00. Following this transaction, Raha directly owns 493,104 shares of Myriad Genetics common stock.
Myriad Genetics Chief People Officer Shereen Solaiman reported a tax-related share withholding connected to vesting restricted stock units. On March 1, 2026, 1,675 shares of common stock were withheld at a price of $4.61 per share to cover tax obligations. After this tax-withholding disposition, Solaiman directly held 109,288 shares of Myriad Genetics common stock.
Myriad Genetics director S. Louise Phanstiel reported open‑market purchases of a total of 104,507 shares of common stock across three days. She bought 6,100 shares on February 25 at $4.736 per share, 50,407 shares on February 26 at $4.803 per share, and 48,000 shares on February 27 at $4.661 per share.
The reported prices are weighted averages for multiple trades executed within disclosed intraday ranges. After these transactions, she held 281,951 shares directly and 33,119 shares indirectly through The Phanstiel Trust.
Myriad Genetics reported an equity award to its Chief Financial Officer, Benjamin Richard Wheeler. On February 2, 2026, he acquired 4,994 shares of common stock at $0 per share, linked to previously granted performance-based restricted stock units (PSUs). These PSUs were originally granted on March 15, 2023, and the Compensation and Human Capital Committee set the final award amount based on performance metrics. Each PSU converts into one share of common stock and will vest on March 15, 2026. After this transaction, Wheeler beneficially owned 97,624 shares directly.
Myriad Genetics Chief Operating Officer Mark Verratti reported an award of common stock tied to earlier performance-based restricted stock units. On February 2, 2026, he acquired 32,810 shares of common stock at $0 per share, following certification of performance goals. After this award, he beneficially owned 414,636 shares directly. The underlying performance-based units were originally granted on March 15, 2023 and are scheduled to vest on March 15, 2026, with each unit representing one share of common stock.
Myriad Genetics reported that its Chief Scientific Officer, Dale Muzzey, received an award of 23,697 shares of common stock on February 2, 2026, at a price of $0 per share, increasing his directly held stake to 193,878 shares.
The shares relate to performance-based restricted stock units initially granted on March 15, 2023. The board’s Compensation and Human Capital Committee determined the final award amount based on pre-set performance metrics, and each unit will convert into one share of common stock vesting on March 15, 2026.
Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share. These shares relate to performance-based restricted stock units (PSUs) that were initially granted on March 15, 2023, with the final award amount determined by the board’s Compensation and Human Capital Committee based on preset performance metrics.
Each PSU represents a right to receive one share of Myriad Genetics common stock and is scheduled to vest on March 15, 2026. After this award, Haas beneficially owns 202,332 shares of Myriad Genetics common stock held directly.
Myriad Genetics reported an insider equity event involving its President and CEO, Samraat S. Raha, who is also a director. On December 11, 2025, 29,634 shares of common stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, as indicated by transaction code F. The shares were valued using the closing price of Myriad common stock on that date, shown as $7.3 per share. After this tax withholding, Raha beneficially owned 453,104 shares of Myriad common stock in direct ownership. This reflects routine equity compensation and related tax settlement activity.
Myriad Genetics (MYGN) filed a Form 4/Exit noting a leadership change. The filing states that, effective on November 3, 2025, the reporting person no longer serves as EVP, Strategy & Transformation and therefore is no longer subject to Section 16 reporting.
The report lists 127,726 shares of common stock beneficially owned directly following the reported event. The form was filed by one reporting person.
Myriad Genetics (MYGN) filed a Form 4 exit notice stating that, effective October 24, 2025, its Chief Accounting Officer, Natalie Munk, no longer serves in that role and is no longer subject to Section 16 reporting. Following the reported change, the filing lists 45,167 shares of common stock beneficially owned, held directly.